The Rosen Law Firm has filed a class action lawsuit against ADMA Biologics, Inc. on behalf of investors who purchased their securities between August 9, 2024, and March 25, 2026. The lawsuit alleges that ADMA Biologics made false and misleading statements by engaging in an undisclosed related party transaction, using channel stuffing to inflate revenue appearances, and lacking adequate internal controls. Investors who wish to serve as lead plaintiff must do so by August 10, 2026.

Pentair PLC (PNR) shares recently fell 4.3% to $71.40, marking it as "Modestly Undervalued" by GuruFocus' GF Value™ estimate of $91.21. The stock's GF Score™ is 81/100, driven by strong valuation and profitability, despite lower momentum. No insider transactions have been reported in the last three months.

This article details Weyerhaeuser's role as a key supplier of dimension lumber for U.S. residential and light commercial construction. It explains how Weyerhaeuser's kiln-dried SPF, Douglas-fir, and Southern Yellow Pine lumber serves as a core commodity for framing, its specifications, and its integration into the company's broader timberland and wood products portfolio. The piece also discusses market dynamics, pricing volatility, and the product's environmental relevance.

First Solar Inc (FSLR) shares increased by 8.8% to $271.17, though GuruFocus's GF Value suggests the stock is 1.6% overvalued. Despite this, FSLR boasts a high GF Score of 91/100, driven by strong financial strength and growth ratings. Insider selling of $17.4 million over the last three months indicates potential caution from those most familiar with the company.

IQVIA Holdings Inc. (IQV) has completed a €950 million senior notes offering due in 2033 with an interest rate of 4.625% per annum. The proceeds will be used to refinance existing debt and cover offering-related fees. This strategic financial move aims to optimize IQVIA's capital structure and enhance its financial flexibility.

DoubleDragon Corp.'s Hotel101-Madrid, its first international hotel, reached full occupancy on June 10, three months after opening. This 680-room property in Madrid generated over $2.3 million in room revenue in the last 30 days. The strong performance reinforces DoubleDragon's "DD Vision 2035" and its strategy to expand the Hotel101 brand globally.

Apogee Therapeutics director Mark C. McKenna was granted stock options for 7,657 shares at an exercise price of $85.00 per share. These options will vest on the one-year anniversary of the June 9, 2026 grant date, provided his continued service, and are set to expire on June 9, 2036. This transaction is categorized as a grant or award acquisition rather than an open-market purchase.

Mexico's Ministry of Economy has streamlined 42 administrative procedures and eliminated one related to mining and extractive activities, marking the most significant operational change since the 2023 Mining Law reform. This overhaul aims to enhance regulatory predictability, a key factor given the increasing geopolitical tensions and global competition for critical minerals impacting Latin American mining investments. Additionally, workers at Newmont’s Peñasquito mine will receive substantial profit-sharing payments, while other news includes tariff modifications, resumption of operations at Orla Mining's Camino Rojo, and a tragic accident at Minera Frisco.

Northrop Grumman Systems Corp.'s Huntsville office has secured a $31 million contract to maintain Poland's WISLA Integrated Air and Missile Defense Battle Command System until 2029. This deal, overseen by the Army Contracting Command in Redstone Arsenal, brings the total cumulative contract cost to $78 million. Poland is enhancing its defense capabilities due to its proximity to Russia and Belarus and the ongoing conflict in Ukraine.

Bernstein initiated coverage on Procter & Gamble (PG) with a Market Perform rating and a $156 price target, citing challenges from private labels and smaller rivals. Despite a strong GF Score™ of 83/100 and a diverse product portfolio, insider selling and lower earnings growth projections suggest potential near-term struggles. The company's P/E ratio is near its 5-year low, indicating it might be undervalued.